Hepatic Cell Plasticity in Chronic Liver Injury

Abstract

Hepatic cell plasticity underlies the liver’s remarkable regenerative capacity, playing a pivotal role in the response to chronic liver injury. This review synthesizes current understanding of cellular plasticity mechanisms, their pathophysiological implications, and the clinical impact in chronic liver diseases. Drawing on recent PubMed-indexed studies and international guidelines, the article discusses epidemiological trends, key risk factors, diagnostic approaches, therapeutic interventions, and emerging innovations targeting cellular plasticity. The content is tailored for clinicians and healthcare professionals seeking an advanced, evidence-based perspective on how hepatic cell plasticity shapes chronic liver injury outcomes and therapeutic strategies.

Introduction

The liver’s unique capacity for regeneration stems from the plasticity of its cellular constituents, enabling adaptation to diverse injuries. Chronic liver injury, resulting from conditions such as viral hepatitis, alcoholic liver disease, and non-alcoholic steatohepatitis (NASH), disrupts this equilibrium and drives pathological remodeling. Understanding how hepatocytes, cholangiocytes, and hepatic progenitor cells interchange roles and phenotypes in response to persistent insult is central to advancing both clinical management and translational research. This review provides a comprehensive overview of the current landscape of hepatic cell plasticity in chronic liver injury, integrating mechanistic insights with clinical implications and directions for future therapy.

Epidemiology / Disease Burden

Chronic liver diseases (CLDs) collectively represent a significant global health burden, with an estimated 2 million deaths annually worldwide. The most common etiologies include chronic viral hepatitis (B and C), alcohol-related liver disease, and NASH. The prevalence of NASH is rising rapidly in parallel with the global obesity epidemic. Persistent injury leads to a spectrum of hepatic responses, from steatosis and inflammation to fibrosis, cirrhosis, and hepatocellular carcinoma. The capacity for hepatic cell plasticity may modulate disease progression, influencing outcomes and the potential for recovery following removal of the underlying insult.

Pathophysiology

Hepatic cell plasticity refers to the ability of liver cells to alter their phenotype and function in response to environmental cues. In chronic injury, mature hepatocytes can dedifferentiate, acquiring progenitor-like features, while cholangiocytes may transdifferentiate toward hepatocyte or ductular phenotypes. Hepatic progenitor cells (HPCs), normally quiescent, become activated during severe or prolonged injury, contributing to ductular reactions and regeneration. Key signaling pathways orchestrating these processes include Notch, Wnt/β-catenin, Hippo/YAP, and Hedgehog. Dysregulation of these pathways can favor fibrogenesis, carcinogenesis, or aberrant regeneration. Recent lineage tracing studies have clarified the dynamic, bidirectional capacity of hepatocytes and cholangiocytes, challenging traditional static models of liver histology and function.

Risk Factors

Major risk factors for chronic liver injury include chronic viral hepatitis (HBV and HCV), excessive alcohol consumption, metabolic syndrome, obesity, insulin resistance, and genetic predispositions such as mutations in PNPLA3. Environmental toxins, certain medications, and autoimmune liver diseases also contribute. Importantly, the nature and duration of injury, as well as host genetic and epigenetic factors, influence the extent and pattern of cellular plasticity. For example, metabolic and toxic injuries more commonly evoke ductular reactions, while viral hepatitis may predominantly affect hepatocyte turnover and transdifferentiation.

Clinical Features

Clinical manifestations of chronic liver injury are typically insidious, including fatigue, malaise, right upper quadrant discomfort, and hepatomegaly. As injury progresses, signs of fibrosis and portal hypertension ascites, varices, hepatic encephalopathy may develop. Biochemically, elevated transaminases, bilirubin, and cholestatic markers (ALP, GGT) are often observed. Histopathology may reveal steatosis, ballooning degeneration, ductular proliferation, and fibrosis. The degree of hepatic cell plasticity, especially the presence of ductular reactions and progenitor cell activation, has been associated with worse prognosis and progression to cirrhosis or hepatocellular carcinoma.

Diagnosis

Diagnosis of chronic liver injury relies on a combination of clinical assessment, laboratory studies, imaging, and liver biopsy. Non-invasive modalities such as transient elastography and serum fibrosis markers help assess fibrosis stage. Immunohistochemical stains (e.g., CK7, CK19, EpCAM) and molecular profiling can identify ductular reactions and progenitor cell activation, serving as surrogate markers for cellular plasticity. Advanced imaging techniques, including multiparametric MRI and PET, are being explored for in vivo assessment of regenerative and fibrogenic activity. Early identification of maladaptive cellular plasticity may inform risk stratification and therapeutic approaches.

Treatment & Management

The mainstay of management is removal or control of the underlying etiology antiviral therapy for hepatitis, abstinence from alcohol, and metabolic risk reduction for NASH. Antifibrotic therapies are under development, with some targeting pathways implicated in cellular plasticity (e.g., Wnt, Hedgehog). Supportive care includes management of complications such as ascites, hepatic encephalopathy, and portal hypertension. Liver transplantation remains the definitive therapy for end-stage disease. Modulation of hepatic cell plasticity is an emerging therapeutic concept, with strategies aimed at promoting regenerative over fibrogenic responses, though clinical translation remains at an early stage.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in the understanding and manipulation of hepatic cell plasticity. Single-cell RNA sequencing and lineage tracing have elucidated the cellular dynamics of regeneration and fibrosis. Novel agents targeting Notch, Hippo/YAP, and Wnt pathways are in preclinical and early clinical trials, aiming to shift the balance toward effective regeneration. Cell-based therapies, including transplantation of progenitor cells or reprogrammed hepatocytes, are being explored, though challenges in engraftment and long-term safety persist. Epigenetic modulators and microRNA-based therapies hold promise for fine-tuning plasticity and inhibiting fibrogenesis or carcinogenesis. Integration of omics technologies is expected to refine patient stratification and guide personalized interventions.

Guideline Recommendations

International guidelines from the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) emphasize etiological treatment, regular monitoring of fibrosis progression, and early recognition of complications. While direct modulation of hepatic cell plasticity is not yet a standard of care, recognition of its role in disease progression supports a multidisciplinary approach to management. Research protocols increasingly include biomarkers of progenitor cell activation and ductular reactions as endpoints, reflecting their prognostic significance.

Conclusion

Hepatic cell plasticity is a fundamental determinant of the liver’s response to chronic injury, dictating the balance between regeneration, fibrosis, and carcinogenesis. Advances in molecular characterization have illuminated the pathways and cellular protagonists involved, offering new therapeutic targets. Clinically, understanding and monitoring cellular plasticity may enhance risk stratification and inform personalized management strategies. Ongoing research and translational efforts are poised to transform the landscape of chronic liver disease care by harnessing the regenerative potential of hepatic cell plasticity.